Tetra Bio-Pharma-Exclusive interview (video)"
On April 19, the company announced plans for the joint distribution of dried medical cannabis in the maritime provinces and Quebec with Aphria Inc. (TSX-V: APH) (OTC: APHQF). The agreement provides the company with dried cannabis for use in its aforementioned clinical trial program while generating near-term revenue to help finance the program’s development. This is a win-win for shareholders and helps the company avoid the cost of establishing its own grow operations. "The team worked closely with U.S. and Canadian regulators to design and implement a Phase I safety trial (ongoing) that will eventually move to a large-scale Phase III efficacy trial targeting pain in patients where opioids and other options have been ineffective. Investors should keep an eye on the stock as these clinical trials progress, since milestone markers could become significant catalysts for the stock price over the coming quarters."
https://www.cannabisfn.com/tetra-bio-pharma-plays-strengths-pharma-approach-plus-exclusive-interview/